High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
<h4>Objectives</h4>We sought to determine the prevalence of phosphodiesterase type 5 inhibitor (PDE-5) mediated drug-drug interactions (DDIs) in males with HIV infection receiving antiretroviral therapy (ART) and identify factors associated with PDE-5-mediated DDIs.<h4>Methods</...
Guardado en:
Autores principales: | Jason M Cota, Taylor M Benavides, John D Fields, Nathan Jansen, Anuradha Ganesan, Rhonda E Colombo, Jason M Blaylock, Ryan C Maves, Brian K Agan, Jason F Okulicz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b77ac608004b4c3eb908b71015873297 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Hepatitis B vaccine responsiveness and clinical outcomes in HIV controllers.
por: Jason F Okulicz, et al.
Publicado: (2014) -
The pharmacological management of erectile dysfunction – Update 2016
por: André Marais
Publicado: (2016) -
Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
por: Antonio Martín Morales, et al.
Publicado: (2009) -
Effect of Modified Vacuum in Patients with Peyronie’s Disease and Erectile Dysfunction
por: Amir Ghasemlouei, et al.
Publicado: (2020) -
Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie’s Disease
por: Yasuyoshi Miyata, et al.
Publicado: (2021)